Every research center and institute at UGA puts quality of life at the forefront of our discoveries. UGA researchers collaborate across departments and disciplines to answer pressing questions about vaccines, immunology, brain science, and more.
Their ultimate question: “How do we change lives and improve our world?”
Driven by this pursuit, our researchers have achieved nearly 56% growth in research expenditures over the past decade.
#7
Best Veterinary School
U.S. News & World Report
#1
U.S. University
for commercial products to market
AUTM
$545.6M
R&D Expenditures
FY2022
One Health
The Precision One Health initiative recognizes the need for an interdisciplinary approach to tackling endemic and emerging diseases. We are unlocking discoveries in disease prevention and treatment using cutting-edge AI and data science methodology.
With a better understanding of how genetics, the environment, and lifestyle affect our health, One Health will help transform how we research and respond to disease management.
A Mission of Research
Our faculty advise the White House, World Health Organization, and FDA on a variety of topics even as they develop research aimed at enhancing the quality of life for people worldwide.
Anumantha Kanthasamy
Anumantha Kanthasamy was appointed as UGA’s inaugural John H. “Johnny” Isakson Chair and Georgia Research Alliance Eminent Scholar in Parkinson’s Research. He also leads the Isakson Center for Neurological Disease Research, which has successfully secured nearly $50M in federal funding to support this important research.
Kanthasamy and his team are pioneering a new approach in the fight against Parkinson’s symptoms. They have gene-edited a probiotic to stimulate the patient’s own body to produce a therapeutic solution.
Mark Tompkins
Mark Tompkins, the UGA Athletic Association Distinguished Professor in Virology and Immunology, and his colleagues in UGA’s Center for Vaccines and Immunology are developing cutting-edge vaccines for infectious diseases.
He is also the director of the Center for Influenza Disease and Emergence Research, which is quickly growing in both influence and impact due to a contract awarded to UGA from the NIH for up to $92M.
Biao He
Biao He, the Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in the Department of Infectious Diseases, has co-founded three companies. His current ventures include Blue Lake Biotechnology, which recently published Phase 1 study results for an intranasal RSV vaccine. Their progress is a major step toward relieving symptoms for the tens of millions of annual RSV-related infections.
These companies develop human and animal vaccines, including the creation of an intranasal treatment against SARS-CoV-2, the causative agent of COVID-19. His expertise and contributions earned him a place on a recent White House panel tasked with providing guidance on the future of COVID-19 vaccines.
Powering Excellence
Strategic investments in research, service, and instruction have sparked a period of remarkable growth at the University of Georgia. They have also solidified UGA’s place among the top universities in the nation.